Bictegravir/emtricitabine/tenofovir alafenamide
| Combination of | |
|---|---|
| Bictegravir | integrase inhibitor |
| Emtricitabine | nucleoside reverse transcriptase inhibitor |
| Tenofovir alafenamide | nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Biktarvy, Taffic |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618012 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains bictegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor; emtricitabine, an HIV-1 nucleoside analog reverse transcriptase inhibitor; and tenofovir alafenamide, an HIV-1 nucleoside analog reverse transcriptase inhibitor.
It was approved for use in 2018 in Australia, the European Union and the United States and in 2019 in New Zealand and the United Kingdom; a generic version was approved by the Drugs Controller General of India in 2019. As of 2024, it is recommended as a first-line choice of antiretroviral therapy in several countries, including the European Union, the United Kingdom and the United States.